We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MS Drug Deal to Net More Than USD 1 Billion

By LabMedica International staff writers
Posted on 30 Aug 2015
Print article
A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases.

Novartis (Basel, Switzerland) recently announced that it would spend more than one billion USD to purchase outstanding rights for the drug Ofatumumab from its manufacturer GlaxoSmithKline (London, United Kingdom).

Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody for the CD20 protein, which appears to inhibit early-stage B lymphocyte activation. It is [US] Food and Drug Administration approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab and has also shown potential in treating follicular non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis, and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia.

Results obtained during a Phase IIa dose finding trial revealed that Ofatumumab led to a “significant reduction of up to 90% in the cumulative number of new brain lesions in patients with MS between weeks 4 to 12 of the study.” No surprising safety events were reported in the study.

GlaxoSmithKline is to receive USD 300 million from Novartis up front with another payment of USD 200 million to follow after the commencement of late-stage clinical trials. GlaxoSmithKline has also been guaranteed royalties of 12% for any future net sales of the compound.

Related Links:
Novartis
GlaxoSmithKline



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.